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Abstract 
Background: Mastocytosis are rare diseases characterized by an accumulation of clonal mast cells (MCs) in one 
or multiple organs or tissues. Patients with systemic mastocytosis (SM), whose MCs frequently arbor the activating 
D816V KIT mutation, may have indolent to aggressive diseases, and they may experience MC mediator related symp‑
toms. Indolent SM with recurrent anaphylaxis or vascular collapse in the absence of skin lesions, ISMs(−), is a specific 
subtype indolent SM (ISM), and this clonal MC activation disorder represents a significant fraction of all MC activation 
syndromes. The V560G KIT mutation is extremely rare in patients with SM and its biological and prognostic impact 
remains unknown.
Case presentation: A 15‑year old boy was referred to our hospital because of repeated episodes of flushing, hypo‑
tension and syncope since the age of 3‑years, preceded by skin lesions compatible with mastocytosis on histopathol‑
ogy that had disappeared in the late‑early childhood. Diagnosis of ISM, more precisely the ISMs(−) variant, was con‑
firmed based on the clinical manifestations together with increased baseline serum tryptase levels and the presence 
of morphologically atypical, mature appearing (CD117+high, FcεRI+) phenotypically aberrant (CD2+, CD25+) MCs, 
expressing activation‑associated markers (CD63, CD69), in the bone marrow. Molecular genetic studies revealed the 
presence of the KIT V560G mutation in bone marrow MCs, but not in other bone marrow cells, whereas the screening 
for mutations in codon 816 of KIT was negative. The patient was treated with oral disodium cromoglycate and the dis‑
ease had a favorable outcome after an eleven‑year follow‑up period, during which progressively lower serum tryptase 
levels together with the fully disappearance of all clinical manifestations was observed.
Conclusions: To the best of our knowledge this first report of a patient with ISM, whose bone marrow MCs carry 
the KIT V560G activating mutation, manifesting as recurrent spontaneous episodes of flushing and vascular collapse 
in the absence of skin lesions at the time of diagnosis, in whom disodium cromoglycate had led to long term clinical 
remission.
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Background
Mastocytosis are rare diseases characterized by an accu-
mulation of clonal mast cells (MCs) in one or multiple 
tissues, whose clinical manifestations mostly depend on 
the overall MC burden, the organs and/tissues involved, 
and the effects of the MC mediators such as histamine, 
leukotrienes, tryptase and heparin [1].
Criteria for the diagnosis and classification of masto-
cytosis were discussed extensively by the experts on the 
subject and consensus proposals were made in the last 
years [2, 3]. These proposals were adopted by the World 
Health Organization (WHO) in 2001 [4] and 2008 [5], 
and lastly updated in 2016 [6]. The 2016 classification 
of the WHO divides the disease into cutaneous masto-
cytosis (CM), systemic mastocytosis (SM), and localized 
mast cell tumors [6, 7]. Cutaneous mastocytosis includes 
maculopapular CM, also known as urticaria pigmentosa, 
diffuse CM, and localized mastocytoma of skin. Sys-
temic mastocytosis is further divided into indolent SM, 
smoldering SM, and advanced SM variants, including 
aggressive SM, mast cell leukemia (MCL), and SM with 
associated hematologic neoplasm (SM-AHN), previ-
ously known as SM with associated clonal hematologic 
non-MC lineage disease (SM-AHNMD) [6, 7]. Other rare 
SM variants have been described so far, such as well-dif-
ferentiated SM (WDSM) [8, 9] and ISM with recurrent 
anaphylaxis or vascular collapse in the absence of skin 
lesions, ISMs(−) [10].
The diagnosis of SM is based on the identification 
of neoplastic MCs by morphological, immunopheno-
typic, and genetic studies in organs and/or tissues out-
side the skin, including mostly the bone marrow (BM), 
and requires at least one major and one minor criteria, 
or three minor criteria [4–7]. The only major criterion 
of SM is the multifocal accumulation and clustering of 
MC (at least 15 MC/cluster) in the BM or another extra-
cutaneous organ. Minor criteria include an abnormal MC 
morphology, expression of CD2 and/or CD25 in MC in 
extracutaneous organs, an activating mutation in codon 
816 of KIT (usually KIT D816V) in extra-cutaneous cells, 
and a basal serum tryptase level exceeding 20  ng/ml. 
Monitoring of serum tryptase is useful both for the diag-
nosis and follow-up of the disease [11].
Indolent SM with recurrent anaphylaxis or vascular 
collapse in the absence of skin lesions, ISMs(−), is a spe-
cific subtype of clonal MC activation disorder (cMCAD) 
[12, 13], and represents a significant fraction of all MC 
activation syndromes (MCAS), a heterogeneous group of 
conditions in which the most prominent clinical mani-
festations result from the release of MC mediators [14, 
15]. The European Competence Network on Mastocy-
tosis (ECNM) classified MCAS into three major groups: 
primary (corresponding to cMCAD), secondary (allergy 
related), and idiopathic (no clonal MCs and MCA trig-
gers identified) [14]. Patients with cMCAD can be fur-
ther subdivided into those fulfilling the WHO criteria for 
the diagnosis of SM and those satisfying only one or two 
minor criteria [14].
Recently, we reviewed the clinical and laboratory fea-
tures of a series of adult patients with mastocytosis 
referred to and followed in a dedicated multidisciplinary 
consultation for mastocytosis in our center [16]. Here we 
describe in detail one of these patients with recurrent 
episodes of vascular collapse, who presented a rare KIT 
V560G activating mutation in bone marrow MCs, and 
had a very favorable outcome after a follow-up of 11-year, 
with a remarkable clinical and laboratory response to oral 
disodium cromoglycate (DSCG).
Case report
A 15  year-old Caucasian male was referenced to our 
institution in November 2005 for investigation of severe 
episodes of flushing, hypotension and vascular collapse 
since his late-early childhood; at that time, he referred 
a past history of several admissions at the emergency 
room for similar episodes. He had no history of urti-
caria, angioedema, and allergy or identified MCA trig-
gers. In particular, the life-threatening episodes were 
not caused by food, medications, insect bites, tempera-
ture changes, exercise, or other recognized factors. Of 
note, the patient had been diagnosed with cutaneous 
mastocytosis at the age of 3-year, based on histopatho-
logical analysis of maculopapular skin lesions which 
disappeared soon thereafter. At the time of referral, he 
didn’t have skin lesions, hepatomegaly, splenomegaly, or 
lymphadenopathy, and he was under H1 anti-histamines 
therapy, without the relief of the crises. Laboratory 
investigation showed markedly increased baseline serum 
tryptase levels (175 μg/l; normal range: 2–13 µg/l). Tran-
sient increase in serum tryptase above the baseline val-
ues during the MC-mediators related events were not 
documented, because blood samples for determination 
of serum tryptase levels were not taken at the episodes 
flushing, hypotension and vascular collapse. The BM 
aspirate was normocellular with increased numbers of 
MC (1.7%), most of which had an atypical (type I) mor-
phology (spindle-shaped MC with irregular distribution 
and focal accumulation of the cytoplasmic granules, and 
elongated cytoplasmic extensions); the myeloid/eryth-
roid ratio was normal and there was no myelodysplasia 
(Fig. 1, panel A). The BM trephine (stained with hema-
toxylin-eosin and Giemsa), showed a normocellular BM 
without dysplastic features or increased blast cells, but 
a few scattered morphologically abnormal MCs, diffi-
cult to recognize (Fig.  1, panel B). Dense BM mast cell 
aggregates (>15  cells/aggregate) were not observed. 
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Flow cytometry confirmed the presence of BM mast 
cells with abnormally high light scatter values (SSC and 
FSC), and a mature (CD117+high, FcεRI+high), but 
aberrant (CD2+, CD25+) and activated (CD63+high, 
CD69+high) phenotype (Fig.  2, panel A). Molecular 
analysis showed the absence of the KIT Asp-816(r)Val 
mutation; in contrast, the KIT Val-560(r)Gly activat-
ing mutation was detected in FACS-purified BM mast 
cells (Fig. 2, panel B), but not in other BM myeloid and 
lymphoid cells, including BM precursors. Serum IgE 
levels were within normal values (7  KU/l; normal lev-
els  <100  KU/l), and the screening for IgE antibodies 
specific for common food and inhalant allergens and 
Hymenoptera venom was negative. The remaining work-
up, which included a full blood cell count, biochemical 
tests, bone densitometry and abdominal ultrasound, 
was unremarkable. Thus, although the patient had no 
skin lesions since his late childhood, the case fulfilled 
the WHO criteria for the diagnosis of ISM. Based on 
these findings and on the clinical manifestations, the 
patient was diagnosed with the ISMs(−) variant [12, 13]. 
H1 anti-histamines were maintained and oral DSCG 
(200 mg capsules, administered 5-times/day) was added. 
Since the start of DSCG therapy, systemic MC-associ-
ated symptoms have remained under control and serum 
tryptase levels progressively decreased over time, from 
175 µg/l in November 2005 (first observation) to 61 µg/l 
in 2008, 49  µg/l in 2011, 45  µg/l in 2013, 31  µg/l in 
August 2015 and 35 µg/l in September 2016 (last obser-
vation). The patient is currently 26  years-old and he 
remains completely asymptomatic under DSCG therapy. 
Methods
Serum tryptase levels were measured by using the Uni-
CAP tryptase fluoroenzyme immunoassay (Pharma-
cia Diagnostics AB, Uppsala, Sweden). The presence of 
IgE antibodies to the mixtures of common inhalant and 
food allergens was screened with the ImmunoCAPT™ 
Phadiatop  Infant® (Pharmacia Diagnostics AB, Uppsala, 
Sweden).
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Fig. 1 Bone marrow cytological and histopathological features at diagnosis. a Leishman’s (A1), toluidine blue (A2) and chloroacetate esterase (A3) 
staining of bone marrow (BM) smears from the patient at diagnosis, revealing atypical mast cells (MCs) with elongated cytoplasmic extensions and 
abnormal granulation (*). A normal MC is shown for comparison (A1, **). b Hematoxilin‑eosin (B1, 40×; B2, 400×), Giemsa staining (B3, 400×) and 
CD117 immunostaining (B4, 400×) of a BM trephine biopsy from the patient at diagnosis, showing normocellular marrow with osteosclerosis (B1, *) 
and scattered elongated and degranulated abnormal (B2 and B3, *), CD117 positive (B4) MCs
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Fig. 2 Immunophenotypic and genetic features of bone marrow (BM) mast cells (MCs). a Illustrating bivariate dot‑plots of the BM cells from the 
patient (panel A1), and after selecting specifically for BM mast cells (panels A2–A4); as illustrated, bone marrow MCs showed a mature (CD117+high, 
FcεRI+high) (panel A2), aberrant (CD2+, CD25+) (panel A3) immunophenotype, with expression of activation‑associated markers (CD63, CD69) in 
a large fraction of the cells (panel A4). Corresponding dot plots from normal bone marrow MCs (blue dots) are show for comparison. b Sequences of 
polymerase chain reaction (PCR) products illustrating the presence of the KIT V560G mutation in bone marrow MCs from the patient, at diagnosis 
(panel B2); the wild‑type (WT) sequence is shown for comparison
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Flow cytometry immunophenotyping of BM mast cells 
was performed using a stain-lyse-and-then-wash direct 
immunofluorescence technique (BD FACS Lysing Solu-
tion™, Becton Dickinson Biosciences, BD, CA, USA), 
accordingly to the recommendations of the REMA [17]. 
Briefly, BM cells were stained with 4-color combinations 
of monoclonal antibodies directed against the CD45, 
CD117, CD2, CD25, CD63, CD69 and FcεRI, conjugated 
with fluorescein isothiocyanate (FITC), phycoerythrin 
(PE), peridinin chlorophyll protein (PerCP) or allophy-
cocyanin (APC). Anti-CD45 (PerCP) and anti-CD117 
(APC) were combined in different tubes with anti-IgE 
(FITC)+anti-CD33 (PE), anti-CD2 (FITC)+anti-CD25 
(PE), or anti-CD63 (FITC)+anti-CD69 (PE). Data acqui-
sition was performed in a FACSCalibur flow cytometer 
(BD), using the BD CellQuest™ software (BD). In the 
first step, 50,000 events from the whole BM cells were 
acquired per tube, and CD117+ high BM mast cells, were 
quantified. In the second step, acquisition though a live 
gate specifically drawn to include only BM mast cells was 
performed and only the events included in this region 
were stored. For data analysis, the Infinicyt™ software 
(version 17.0, Cytognos, Salamanca, Spain) was used. 
Mast cells were first identified based on their typical 
CD45+CD117+high phenotype and then characterized 
for the expression of other cell surface markers.
KIT mutations were detected in highly purified (>97% 
purity) BM cell populations as previously described 
in detail [18]. Positivity for the KIT V560G mutation 
was confirmed by sequencing the PCR products in 
both directions in an ABI Prism 3130 Genetic Analyzer 
(Applied Biosystems, Foster City, CA), using the 5′-CCA 
GAG TGC TCT AAT GAC TG-3 and 5-AGC CCC TGT 
TTC ATA CTG AC-3 primers (Isogen Life Sciences) and 
the dye-deoxy terminator method.
Discussion
The case here reported fulfills the WHO criteria for the 
diagnosis of SM, with three minor diagnostic criteria 
being present: increased baseline serum tryptase levels, 
morphologically atypical and phenotypically aberrant 
(CD2+, CD25+) bone marrow MCs [6, 7]. However, 
in contrast to what is observed in most of the patients 
with ISM, the KIT D816V mutation was absent [19, 20]. 
Instead, the BM mast cells, but not other BM cells, were 
found to have the KIT V560G activating mutation. Inter-
estingly, while skin lesions compatible with mastocyto-
sis had occurred at the age of 3-year, they had regressed 
in the late-early childhood, the only disease-associated 
symptoms that persisted over time being recurrent epi-
sodes of flushing, hypotension and vascular collapse.
Clonal MC activation disorders comprise a heteroge-
neous group of conditions that do not always fulfil the 
WHO criteria for SM; such conditions typically shave 
gain of function KIT mutations associated to constitu-
tively activated MCs [12–15]. The clinical manifestations 
may vary in type and severity, and they usually include 
abdominal cramping, diarrhea, tachycardia, arrhythmias, 
irritability, and/or many other signals and symptoms 
related to the release of MC mediators. As it occurred 
in our patient, life-threatening episodes of anaphylaxis, 
including flushing, hypotension and vascular collapse, 
taking place spontaneously or after a Hymenoptera sting, 
may occur, particularly in patients who show no skin 
lesions typical of mastocytosis [12–15].
Systemic mastocytosis has been associated with the 
presence of somatic mutations in the v-kit Hardy-Zuck-
erman four feline sarcoma viral oncogene homolog (KIT), 
which encodes for a transmembrane protein stem cell 
receptor with kinase activity (KIT receptor, CD117) that 
binds to the stem cell factor (SCF) [21, 22]. Typically, in 
the majority (>90%) of the ISM patients the A71763T 
substitution is detected at codon 816 in exon 17 of the 
KIT gene, whereby an aspartate is changed for a valine 
of the KIT protein sequence [21, 22]. However, other 
uncommon somatic (e.g., V560G, D815K, D816Y, D816F, 
D816H, and D820G) and germline (e.g., F522C, A533D, 
K509I and del419) mutations have been reported in a 
small number of cases [21, 22]. Of note, this is the first 
case described so far in the literature who carried the 
KIT V560G activating mutation.
Two activating point mutations of KIT leading to two 
distinct amino acid substitutions in the KIT receptor, i.e. 
Asp-816(r)Val and Val-560(r)Gly, have been described 
in the MC leukemia cell line (HMC-1), derived from a 
patient with SM [21–23]. The D816V mutation affects the 
activating loop of the KIT receptor and occurs in  >90% 
of adult SM patients [18–21, 24], not only in the BM, 
but also in the peripheral blood [18, 25]. In contrast, the 
V560G mutation involves the juxta membrane domain of 
the KIT receptor and is preferentially found in gastroin-
testinal stromal tumors, been reported in only a few SM 
cases [19, 20, 26–28] (Table  1). In this regard, it should 
be noted that despite the first description of the V560G 
KIT-mutation has been made decades ago, this mutation 
was not found in purified BM mast cells from a series of 
113 adult patients diagnosed with SM at the reference 
centers of the Spanish Network on Mastocytosis (REMA) 
[19], published in 2006. Interestingly, however, it was 
subsequently described to be present in BM mast cells 
from 1 of 123 patients (0.8%) in a subsequent update of 
the REMA 2006 series, published in 2010 [20]. In paral-
lel, the KIT V560G mutation was found in the skin biopsy 
of only 1 CM patient out of 142 adult patients diag-
nosed with mastocytosis at the reference centers of the 
French Mastocytosis Network (AFIRMM) [28], which 
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confirms that this is a rare but recurrent KIT mutation in 
mastocytosis.
Previous studies have emphasized the relevance of per-
forming molecular studies in purified BM mast cells, as 
well as in other BM cells, such as CD34+ precursors and 
mature myeloid and lymphoid BM cells to search not only 
for the KIT D816V mutation, but also for other KIT muta-
tions, particularly if the BM mast cells have an aberrant 
immunophenotype and/or abnormal morphological fea-
tures [19, 20]. In accordance, Garcia-Montero et  al. [19] 
have showed the presence of KIT D816V mutation in vir-
tually all adults (93%) with SM, while other KIT mutations 
were rarely (<3%) detected. In addition, they demonstrated 
that in around one-third of patients with SM, the KIT 
mutation was detected not only in MC, but also in CD34+ 
hematopoietic cells and eosinophils, and, to a lesser extent, 
in monocytic and neutrophil-lineage BM precursor cells 
and lymphocytes [19]. Furthermore, they found that most 
patient with poor-prognosis SM (81%) carried the KIT 
mutation in two or more BM myeloid cell populations, 
while this occurred in a smaller proportion (27%) of indo-
lent SM cases [19]. Moreover, a number of studies have 
suggested that “atypical” (non D816V) KIT mutations may 
facilitate transformation to more advanced MC disease [7]; 
however, the prognostic value of the KIT V560G activat-
ing mutation is not established, due to its rarity. Additional 
mutations in other genes (e.g., TET2, SRSF2, ASXL1, CBL, 
RUNX1, and RAS, and less commonly, JAK2 V617F and 
RUNX1-RUNX1T1) may occur in patients suffering from 
aggressive SM, MCL or SM-AHN, ASM, or MCL [7].
The activating KIT D816V and V560G mutations, 
despite targeting the same receptor, have a distinct 
impact on downstream signaling pathways, at the same 
time they might potentially be targeted by different 
tyrosine kinase inhibitors (TKI) [23]. Thus, the Janus 
kinase 3/signal transducer and activator of transcription 
(JAK3/STAT) pathway is the preferred signaling pathway 
involved in the KIT V560G mutation, whereas the mam-
malian target of rapamycin complex 1/4E-binding pro-
tein 1 (mTORC1/4E-BP1) pathway is preferentially linked 
to the KIT D816V mutation [23].
The KIT D816V mutation, which is found in the 
majority of patients with SM and initiates a number of 
signal transduction events, is thought to trigger abnor-
mal MC activation. However, not all patients with KIT 
D816V  +  SM suffer from MC activation symptoms, 
suggesting that other mechanism may be implicated. 
Unfortunately, till recently the only in vitro model avail-
able for studying the impact of KIT mutations on human 
MC biology was the HMC-1 cell line, which arbor the 
KIT V560G mutation. Two sublines of HMC-1 were sub-
sequently described, named HMC-1.1 (KIT V560G+) 
and HMC-1.2 (KIT V560G+, KIT D816V+) [29]. How-
ever, the fact that both HMC-1 sublines contain the 
KIT V560G mutation, whereas only the HMC-1.2 sub-
line exhibits the KIT D816V mutation, makes it difficult 
to compare the signaling pathways activated by each of 
the mutant forms of KIT. To overcome these limitations, 
Saleh et al. [30] have recently established a KIT D816V+ 
SCF-independent MC line (ROSAKIT D816V), for which 
a KIT SCF-dependent wild type (ROSAKIT WT) exists. 
They found that ROSAKIT D816V cells produce a MC 
tumors in mice models, but, unexpectedly, ROSAKIT 
D816V cells exhibited a decreased responsiveness to IgE-
dependent stimuli as compared to ROSAKIT WT cells, 
and mice with ROSAKIT D816V-derived MC tumors 
Table 1 Frequency of KIT codon 816 and 560 mutations in patients with mastocytosis
CM cutaneous mastocytosis, SM systemic mastocytosis, NA not available
Reference Büttner et al. [26] Yanagihori et al. [27] Garcia-Montero et al. [19] Teodosio et al. [20] Lanternier et al. [28]
Country Germany Japan Spain Spain France
Number of patients studied 17 16 113 123 142
Adults/children 6/11 12/4 113/0 123/0 142/0
Males/females NA 12/4 58/55 66/57 43/93
CM/SM 17 (100%)/0 (0%) 16 (100%)/0 (0%) 0 (0%)/113 (100%) 0 (0%)/123 (100%) 38 (27%)/104 (73%)
Adult/childhood onset 6 (35%)/11 (65%) 4 (25%)/12 (75%) NA/NA NA/NA 114 (80%)/28 (20%)
Sample types tested Skin Skin Bone marrow Bone marrow Skin
Cell types tested All cells All cells Mast cells Mast cells All cells
KIT codon 816 mutations 6/17 (35%) 14/16 (88%) 102/113 (90%) 93/123 (6%) 97/138 (70%)
 Adult onset 6/6 (100%) 4/4 (100%) NA NA 86/112 (77%)
 Children onset 0/11 (0%) 10/12 (83%) NA NA 11/26 (42%)
KIT codon 560 mutations 2/6 (33%) 0/16 (0%) 0/113 (0%) 1/123 (0.8%) 1/138 (0.7%)
 Adult onset 2/4 (50%) 0/4 (0%) NA NA 1/112 (0.9%)
 Children onset 0/2 (0%) 0/12 (0%) NA NA 0/26 (0%)
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did not show MC mediator-related symptoms. In addi-
tion, they realized that KIT D816V+ MC obtained from 
patients with SM did not show increased IgE-dependent 
histamine release. They concluded that KIT D816V muta-
tion does not activate MC to release proinflammatory 
mediators, and they proposed that MC mediator-related 
symptoms in patients with SM occur preferentially in the 
context of a coexisting allergy [30]. Our patient, whose 
BM mast cells harbor the KIT V560G mutation, had MC-
mediator related events without clinical or laboratory 
evidence of allergy, as documented by normal serum IgE 
levels and negative screening for IgE antibodies specific 
for food and inhalant allergens. Thus, it would be of inter-
est to explore whether KIT V560G promotes, instead of 
suppressing, IgE-mediated histamine release.
Overall, three distinct MC immunophenotypic pro-
files (mature, activated and immature) were described so 
for patients with SM, which correspond to different dis-
ease subtypes, namely WDSM, ISM/cMCAD and ASM/
MCL, respectively [20]. So, BM mast cells from patients 
with ISM and cMCAD have a high light scatter, a mature 
(CD117+high, FcεRI+high), activated (overexpression of 
CD63, CD69, CD203c, and other activation related mark-
ers) and aberrant (CD25+, CD2+) phenotype, as found 
in this case.
Symptomatic treatment of SM is mainly based on 
avoidance of factors triggering the release of MC media-
tors and may also include H1 and H2 anti-histamines, 
proton pump inhibitors, anti-leukotrienes, anti-choliner-
gic, corticosteroids, DSCG, and/or epinephrine in case of 
anaphylactic episodes. In aggressive SM, treatment with 
interferon alpha, cladribine (2-chlorodeoxyadenosine) or 
TKIs should to be considered. Concerning TKIs, imatinib 
mesylate is effective only in patients who do not carry the 
KIT D816V mutation or other exon 17 mutations [31]. 
The patient here reported, showing limited tumor bur-
den and life-threatening episodes of vascular collapse, 
required only symptomatic therapy.
Cromoglicic acid (also known as cromoglycate or cro-
molyn), which is marketed as a sodium salt (disodium 
cromoglycate, DSCG, or cromolyn sodium), belongs to 
the group of chromones and is a mast cell stabilizer that 
prevents the release of MC mediators [32, 33]. Its mecha-
nism of action remains poorly understood [32, 33]. DSCG 
has minimal systemic absorption following ingestion and 
negligible fat solubility, suggesting an inability to enter 
the cells and an interaction with a cell surface recep-
tor [32, 33]. In permeabilized mast cells, DSCG inhibits 
GTP-gamma-S-induced secretion by a mechanism not 
involving the nucleoside diphosphate kinase [34]. In acti-
vated neutrophils DSCG selectively inhibits  O2—genera-
tion but not degranulation and such effect may be related 
with inhibition of assembly of an active NADPH oxidase 
and prevention of oxygen radical-induced tissue dam-
age [35]. Inhibition of MC-mediated immediate-type 
hypersensitivity by DSCG has also been reported [36]. 
In addition, DSCG was found to be a G-protein-coupled 
receptor 35 agonist [37]. However, the exact biochemi-
cal basis of the response of MC carrying activating KIT 
mutations to DSCG are not known and it would be inter-
esting to investigate if the KIT receptor itself or down-
stream signaling pathway components may serve as 
targets for this MC stabilizer.
Disodium cromoglycate is available as nasal spray (for 
allergic rhinitis), eye drops (for allergic conjunctivitis), 
and oral forms (capsules and aqueous solution, used 
to treat urticaria, ulcerative colitis, and mastocytosis), 
although availability varies from one country to another. 
Cromolyn sodium, capsules (100  mg) and oral solution 
concentrate (100  mg/5  ml), was approved by the Food 
and Drug Administration for the treatment of mastocy-
tosis in adults and children aged more than 2 years-old, 
being licensed for that in the United States (capsules and 
ampules) and in Canada (capsules). In that concerning 
the effectiveness of DSCG in treatment of mastocytosis, 
the randomized controlled trials performed are scarce 
(we have found only four studies published in journals 
indexed in MedLine), historic (reported from 1979 to 
1990), and small (enrolling 5–13 patients/trial); they have 
used variable doses of DSCG (200  mg taken orally four 
times daily in most cases) in different formulations (cap-
sules, tablets or oral aqueous solution) and the results 
obtained were not totally concordant [38–41]. In the late 
70s, a double-blind crossover study of the efficacy of oral 
DSCG was carried out in 5 patients with SM for periods 
of 8–32  months; the authors observed that DSCG (but 
not placebo) produced marked amelioration of the pru-
ritus, flushing, diarrhea, abdominal pain and disorders 
of cognitive function [38]. In the 90s, a double-blind, 
placebo-controlled trial of the efficacy of oral DSCG was 
conducted in 11 patients with SM; this study showed 
that DSCG was significantly helpful relative to placebo in 
alleviating the gastrointestinal manifestations, whereas 
the benefit for non-gastrointestinal symptoms did not 
reach statistical significance [39]. In between these stud-
ies, two other trials were published. In one of them, 13 
patients (3 children and 10 adults) with mastocytosis 
having cutaneous and systemic symptoms participated in 
a blind trial and were treated for 1 month with placebo 
and for another month with oral DSCG; it was found 
that most patients experienced amelioration of the pru-
ritus, improvement in urtication and relief of gastroin-
testinal manifestations when treated with DSCG [40]. 
The other study compared the efficacy of oral DSCG and 
combined H1 and H2 antihistamines [41]. In this study, 
8 patients with SM were randomly assigned to receive 
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either DSCG  +  placebo or antihistamines  +  placebo, 
with crossover at the end of week 10, and only 6 patients 
completed the study; although the differences between 
the two treatments were not statistically significant, the 
authors noted that most patients had less pruritus and 
less urticaria while receiving antihistamines, while most 
patients had improvement of the gastrointestinal symp-
toms and one patient experienced dramatic relief from 
bone pain while receiving DSCG [41]. In addition, case 
reports and small series of patients have stated benefits 
in using oral and topical DSCG for the treatment of dif-
fuse cutaneous/bullous mastocytosis [42–44]. Moreover, 
oral and inhaled DSCG have been used in the manage-
ment of other symptoms associated with SM, such as of 
bone pain, headache and fatigue, and hypotensive crisis 
[45, 46]. Despite the low level of evidence found in the 
literature, DSCG is one of the mainstays in the symp-
tomatic treatment of SM, being recommended by the 
experts from centers where a large number of patients 
with mastocytosis are followed, to alleviate gastrointesti-
nal, cutaneous, neuropsychiatric, skeletal and other sys-
temic disease related symptoms [47–49].
In Portugal, DSCG is not approved for the treatment of 
mastocytosis and the drug is not available in oral formu-
lations. Our patient was treated off-label with manipu-
lated gelatinous capsules containing 200  mg DSCG; as 
described, this therapeutic approach successfully abro-
gated the clinical manifestations related to the release 
of MC mediators, and might therefore be a non-toxic 
treatment option for this very small and unique subset 
of SM patients. Because childhood onset mastocytosis 
often regresses spontaneously by puberty, the possibil-
ity of the disappearance of the clinical manifestations in 
our patient being due to spontaneous regression of the 
disease with the advancing age cannot be completely 
excluded. However, this hypothesis seems improbable: 
first, when the patient was first observed in our consulta-
tion he had already 15 years old and he still had very high 
basal serum tryptase levels (13 times the upper limit of 
normal) and frequent episodes of flushing, hypotension 
and vascular collapse; second, there was a clear relation-
ship between the beginning of DSCG treatment and the 
control of the clinical manifestations, with no such epi-
sodes being observed thereafter. In addition, although 
basal serum tryptase levels have declined steadily over 
the years after starting DSCG therapy, they were still 
increased at the last observation (2.6 times the upper 
limit of normal), indicating that the disease remains 
active, although clinically controlled.
In summary, here we described a young patient with 
SM whose the BM mast cells were found to harbor the 
activating KIT V560G mutation, in association with a 
mature, activated, and aberrant phenotype, who showed 
a sustained complete response of MC activation-associ-
ated life-threatening symptoms with long term therapy 
with DSCG.
Conclusions
Patients with SM, whose MCs frequently arbor the 
activating D816V KIT mutation, may have indolent to 
aggressive diseases, and they may experience diverse 
types of MC mediator symptoms. In contrast, the V560G 
mutation, which uses different signaling pathways to pro-
mote MC growth, is extremely rare and its biological and 
prognostic impact remains unknown. Here we reported 
a patient with recurrent spontaneous episodes of severe 
flushing and vascular collapse, who harbor the V560G 
KIT mutation in mature activated aberrant BM mast 
cells, in whom DSCG treatment had led to long term 
clinical remission.
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